---
figid: PMC4959441__nihms-775218-f0001
figtitle: RAS-mediated signal transduction pathways and post-translational modification
  of RAS
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Saccharomyces cerevisiae
- Rat sarcoma virus
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC4959441
filename: nihms-775218-f0001.jpg
figlink: /pmc/articles/PMC4959441/figure/F1/
number: F1
caption: RAS-mediated signal transduction pathways and post-translational modification
  of RAS. (A) The RAS-RAF-MEK-ERK is commonly implicated as the primary signaling
  pathway of RAS. Ligand activated RTKs in turn activate GEFs, which catalyze the
  formation of RAS-GDP, the inactive form, into RAS-GTP, the active form. RAS-GTP
  then acts on multiple downstream effectors, including PI3K and RAL pathways. (B)
  Post-translational modification of RAS C termini include multiple enzyme-catalyzed
  lipidation processes. Farnesylation (blue diamond) occurs on the Cys of the conserved
  CAAX region of the C termini. RAS then undergoes a proteolytic clearvage of AAX
  and carboxymethalation. The isoforms HRAS, NRAS, and KRas4A additionally undergo
  palmitoylation (orange diamond). PDEδ and Galactin escort RAS for its ultimate recruitment
  into the plasma membrane. * Indicates enzymes currently targeted in studies for
  RAS inhibition related to RAS trafficking.
papertitle: Therapeutic Approaches to RAS Mutation.
reftext: Aaron J Scott, et al. Cancer J. ;22(3):165-174.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9533616
figid_alias: PMC4959441__F1
figtype: Figure
redirect_from: /figures/PMC4959441__F1
ndex: fd6661b1-deba-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4959441__nihms-775218-f0001.html
  '@type': Dataset
  description: RAS-mediated signal transduction pathways and post-translational modification
    of RAS. (A) The RAS-RAF-MEK-ERK is commonly implicated as the primary signaling
    pathway of RAS. Ligand activated RTKs in turn activate GEFs, which catalyze the
    formation of RAS-GDP, the inactive form, into RAS-GTP, the active form. RAS-GTP
    then acts on multiple downstream effectors, including PI3K and RAL pathways. (B)
    Post-translational modification of RAS C termini include multiple enzyme-catalyzed
    lipidation processes. Farnesylation (blue diamond) occurs on the Cys of the conserved
    CAAX region of the C termini. RAS then undergoes a proteolytic clearvage of AAX
    and carboxymethalation. The isoforms HRAS, NRAS, and KRas4A additionally undergo
    palmitoylation (orange diamond). PDEδ and Galactin escort RAS for its ultimate
    recruitment into the plasma membrane. * Indicates enzymes currently targeted in
    studies for RAS inhibition related to RAS trafficking.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Arhgef2
  - Sergef
  - ras
  - Hras
  - Kras
  - Rem1
  - Och
  - Rap1gap
  - Rasa1
  - Zhx2
  - Ralgds
  - Nras
  - Mdk
  - Map2k1
  - Map2k2
  - Rala
  - Ralb
  - Pik3r1
  - Rce1
  - Sec1
  - Ephb2
  - Mapk1
  - Mapk3
  - Akt1
  - Mtor
  - Coch
  - Pik3cg
  - Stxbp1
  - Ephb1
  - EGFR
  - ARHGEF2
  - SLC2A4RG
  - XYLT2
  - SOS1
  - SOS2
  - KRAS
  - HRAS
  - NRAS
  - COCH
  - RASA1
  - RGS6
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - RALGDS
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RALA
  - RALB
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - RCE1
  - SEC1P
  - EPHB2
  - MAPK1
  - MAPK3
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - PDZ-GEF
  - garz
  - RhoGEF64C
  - pbl
  - Sos
  - Ras64B
  - Ras85D
  - galectin
  - Gapdh2
  - CdGAPr
  - Gapdh1
  - RasGAP1
  - ArfGAP1
  - Raf
  - Rgl
  - Dsor1
  - Mtk
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Rop
  - Sec61beta
  - Erk7
  - rl
  - Akt
  - Tor
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
